Paradigm Health's Significant Funding Round
Paradigm Health, a leading technology firm working to reshape the clinical research landscape, has successfully secured an impressive $78 million Series B funding. This financing round, which was oversubscribed, saw participation from prominent investors including ARCH Venture Partners, DFJ Growth, and other existing backers such as F-Prime and Lux Capital. The funds are poised to bolster the company's mission of making clinical trials more embedded in everyday patient care, providing greater accessibility.
Enhancing Clinical Trials for Better Access
The investment gained through the Series B round is earmarked for accelerating Paradigm Health's expansion efforts. Particularly, there has been a noticeable demand from biopharmaceutical companies wanting more efficiency in conducting clinical trials. Moreover, health systems are also increasingly eager to provide closer access to trial opportunities for their patients. Currently, Paradigm Health is responsible for supporting Phase I-III oncology studies for a substantial number of leading global pharmaceutical companies.
Innovative Infrastructure for Medical Research
Robert Nelsen, a Managing Partner at ARCH Venture Partners and a Co-Founder of Paradigm Health, shared insights on the significance of efficient trials stating, "When trials run more efficiently, new treatments reach patients sooner." He emphasized that Paradigm Health is building essential infrastructure within the industry. By creating a unified platform, hospitals and sponsors can conduct studies more efficiently, reducing costs substantially. This advancement is geared toward speeding up the availability of promising therapies to patients in need.
Expanding Reach Beyond Cancer Trials
Since the acquisition of Flatiron Health's Clinical Research Business, Paradigm Health has established itself as the largest oncology research network in the country. As it broadens its focus, the company is poised to venture into other significant medical areas such as neuroscience and cardiovascular diseases, highlighting a commitment to fulfilling critical research needs not only in oncology but across multiple therapeutic fields.
Transforming Community Access to Clinical Research
Access to clinical trials has traditionally been limited, especially for patients located in community and rural settings. Kent Thoelke, the Chief Executive Officer of Paradigm Health, articulated the necessity for improving care through wider participatory access in clinical trials. By embedding trials directly into routine clinical workflows, Paradigm Health is creating an ecosystem that enables various health systems to engage in research with fewer resources.
Achieving Nationwide Coverage
Paradigm Health's platform is now active in 45 states across the U.S., serving 166 healthcare organizations and providing access to 2,100 locations. This robust network ensures that a significant portion of the U.S. cancer population can conveniently reach a clinical trial site. With the integration of AI to automate patient matching and enhance site feasibility, Paradigm Health has managed to optimize trial enrollment, accelerating processes for biopharmaceutical sponsors.
Pioneering the Future of Clinical Trials
Commenting on the future landscape of clinical trials, Justin Kao from DFJ Growth noted, "Clinical trials are the bottleneck in getting new therapies to patients." The importance of AI-driven strategies cannot be overstated as they present an unprecedented opportunity for innovation in drug development. Paradigm Health is positioning itself at the forefront of this shift, banking on its advanced technology and expansive clinical network to enhance trial accessibility and efficiency.
About Paradigm Health
Paradigm Health is on a mission to reshape the clinical research ecosystem. Their advanced platform is designed to facilitate equitable access to clinical trials, ultimately increasing participation and enhancing trial efficiencies. Backed by prominent investors, Paradigm Health is committed to dismantling barriers in the clinical research environment, ensuring that life-saving therapies become accessible to a broader patient population. To explore more about what Paradigm Health has to offer, visit their official website.
Frequently Asked Questions
What is the purpose of Paradigm Health's recent funding?
The funding will support Paradigm Health in expanding their clinical trial platform and enhancing patient access to trials.
How does Paradigm Health improve patient access to clinical trials?
By embedding trials into routine clinical workflows and remote settings, Paradigm Health enables health systems to participate in research more easily.
What types of clinical trials does Paradigm Health support?
The company primarily supports oncology trials but is expanding into neuroscience and other significant medical areas.
What role does technology play in Paradigm Health's operations?
Paradigm Health uses AI to streamline patient matching and site feasibility, accelerating the trial process significantly.
Who are the key investors in Paradigm Health?
Prominent investors include ARCH Venture Partners, DFJ Growth, and other notable funds interested in the healthcare sector.
